Related Experiment Videos
Optimized multiplex IgH/ras PCR: a tool for quantitative monitoring of B-lymphoproliferative disorders
A Slavícková1, V Ullmannová, P Klener
1Charles University, 1st Department of Internal Medicine, Prague, Czech Republic.slavikov@mbox.cesnet.cz
Insights
Quantitative PCR effectively monitors residual hematological malignancies. This method uses immunoglobulin heavy chain (IgH) and Hras 1 (ras) genes to detect increases in malignant cells, aiding treatment assessment.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Monitoring minimal residual disease (MRD) is crucial for hematological malignancies.
- Quantitative PCR (qPCR) offers a sensitive method for MRD detection.
Purpose of the Study:
- To develop and validate a multiplex PCR assay for quantifying residual hematological malignancies.
- To assess the utility of this assay in monitoring B-lymphoproliferative disorders.
Main Methods:
- A multiplex IgH/ras PCR was designed, co-amplifying the IgH CDR3 rearrangement (disease marker) and Hras 1 gene segment (control).
- Serial dilutions of diagnostic DNA were analyzed via PCR in a sub-plateau phase.
- Densitometry was used to quantify PCR products, relating the IgH CDR3 product to the ras product ratio.
Main Results:
- An increased IgH/ras ratio indicated an increase in malignant cells.
- The assay demonstrated applicability in monitoring B-cell non-Hodgkin's lymphoma.
- The method provides quantitative information on disease activity and treatment response.
Conclusions:
- The multiplex IgH/ras PCR is a viable quantitative approach for monitoring residual hematological malignancies.
- This technique can offer valuable insights into disease progression and treatment efficacy.
- Further application in B-lymphoproliferative disorders is supported by these findings.
Abstract:
The use of quantitative PCR is recommended to monitor the level of residual hematological malignancies. The proposed multiplex IgH/ras PCR uses a co-amplification of the clonal CDR3 rearrangement of the immunoglobulin heavy chain gene (IgH) as a disease marker and a segment of the Hras 1 gene containing codon 61 (ras) as a control gene. Serial dilutions of stored diagnostic DNAs are examined together in the same PCR at a sub-plateau phase and, after analysis by densitometry, the amount of CDR3 product is related to the ras product. An increase of this ratio at comparable amounts of DNA is viewed as an increase of malignant cells. This endpoint PCR quantifying approach appears to be applicable in monitoring B-lymphoproliferative disorders as was shown to be true in B-cell non-Hodgkin's lymphoma and may provide information on disease activity and treatment outcome.